The emerging role of medical affairs within the modern pharmaceutical company

被引：0

作者：

Wolin, MJ ^{[1
]}

Ayers, PM ^{[1
]}

Chan, EK ^{[1
]}

机构：

[1] Chiron Corp, Dept Med Affairs, Emeryville, CA 94608 USA

来源：

DRUG INFORMATION JOURNAL | 2001年 / 35卷 / 02期

关键词：

medical affairs; drug development; regulations; medical science liaison;

D O I：

暂无

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Medical affairs groups are an increasingly vital part of the modem pharmaceutical company. This review will highlight the major functions, customary organizational structure, and responsibilities of medical affairs departments. These groups perform a wide range of activities often overlapping with sales, marketing, clinical development, and customer service. Medical affairs personnel must strive for the highest scientific integrity in order to produce successful clinical trials and provide the greatest support for the market. It is important that they well understand the regulations surrounding their activities and appreciate the commercial implications of their work. How well the medical affairs group maintains this delicate balance will determine its overall success.

引用

页码：547 / 555

页数：9

共 36 条

[21] INTERFERON-ALPHA IN PATIENTS WITH ASYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION - A RANDOMIZED, PLACEBO-CONTROLLED TRIAL [J].

LANE, HC ;

DAVEY, V ;

KOVACS, JA ;

FEINBERG, J ;

METCALF, JA ;

HERPIN, B ;

WALKER, R ;

DEYTON, L ;

DAVEY, RT ;

FALLOON, J ;

POLIS, MA ;

SALZMAN, NP ;

BASELER, M ;

MASUR, H ;

FAUCI, AS .

ANNALS OF INTERNAL MEDICINE, 1990, 112 (11) :805-811

[22] FREE AND LIPOSOMAL DOXORUBICIN TREATMENT OF INTRAPERITONEAL COLON-26 TUMOR - THERAPEUTIC AND PHARMACOLOGICAL STUDIES [J].

MAYHEW, E ;

CIMINO, M ;

KLEMPERER, J ;

LAZO, R ;

WIERNIKOWSKI, J ;

ARBUCK, S .

SELECTIVE CANCER THERAPEUTICS, 1990, 6 (04) :193-209

[23] CHOP-BLEO PLUS INTERFERON FOR STAGE-IV LOW-GRADE LYMPHOMA [J].

MCLAUGHLIN, P ;

CABANILLAS, F ;

HAGEMEISTER, FB ;

SWAN, F ;

ROMAGUERA, JE ;

TAYLOR, S ;

RODRIGUEZ, MA ;

VELASQUEZ, WS ;

REDMAN, JR ;

GUTTERMAN, JU .

ANNALS OF ONCOLOGY, 1993, 4 (03) :205-211

[24]

MILLER RL, 1989, CANCER RES, V49, P1871

[25] Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers [J].

Muggia, FM .

DRUGS, 1997, 54 (Suppl 4) :22-29

[26] Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation [J].

Muggia, FM ;

Hainsworth, JD ;

Jeffers, S ;

Miller, P ;

Groshen, S ;

Tan, M ;

Roman, L ;

Uziely, B ;

Muderspach, L ;

Garcia, A ;

Burnett, A ;

Greco, FA ;

Morrow, CP ;

Paradiso, LJ ;

Liang, LJ .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :987-993

[27] Doxil in breast cancer [J].

Muggia, FM .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :811-811

[28] COMBINATION TRIAL OF SUBCUTANEOUS RECOMBINANT ALPHA-2B INTERFERON AND ORAL CYCLOPHOSPHAMIDE IN FOLLICULAR LOW-GRADE NON-HODGKINS-LYMPHOMA [J].

OZER, H ;

ANDERSON, JR ;

PETERSON, BA ;

BUDMAN, DR ;

COOPER, MR ;

KENNEDY, BJ ;

SILVER, RT ;

HENDERSON, ES ;

DUGGAN, DB ;

BARCOS, M ;

BLOOMFIELD, CD ;

GOTTLIEB, AJ .

MEDICAL AND PEDIATRIC ONCOLOGY, 1994, 22 (04) :228-235

[29]

Perez EA, 1996, SEMIN ONCOL, V23, P41

[30] Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial [J].

Ranson, MR ;

Carmichael, J ;

OByrne, K ;

Stewart, S ;

Smith, D ;

Howell, A .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (10) :3185-3191

← 1 2 3 4 →